PROJECT AGREEMENT 1 TO THE PRODUCT DEVELOPMENT AGREEMENT BETWEEN RRD INTERNATIONAL, LLC AND EIGER BIOPHARMACEUTICALS, INC. Product Development of Eiger’s HDV ProgramProject Agreement • November 9th, 2018 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Project Agreement 1 (this “Project Agreement”), effective July 1, 2018 (the “Project Agreement Effective Date”), is between Eiger BioPharmaceuticals, Inc. (“Eiger”) and RRD International, LLC (“RRD”) and relates to the Product Development Agreement dated July 1, 2018 (the “Agreement”). Pursuant to the Agreement, RRD has agreed to perform certain services in accordance with written Project Agreements, such as this one, entered into from time-to-time describing such services. Capitalized terms used herein, and not otherwise defined, shall have the meanings given such terms in the Agreement.
PRODUCT DEVELOPMENT AGREEMENTProduct Development Agreement • November 9th, 2018 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
This Product Development Agreement (this “Agreement”) is effective July 1, 2018 (the “Effective Date”) and is between RRD International, LLC, a Delaware limited liability company with offices at 7361 Calhoun Place, Suite 510, Rockville, MD 20855 (hereinafter “RRD”) and Eiger BioPharmaceuticals, Inc., a Delaware corporation with executive offices at 2155 Park Boulevard., Palo Alto, CA 94306 (hereinafter “Eiger”). Each of RRD and Eiger is a “Party” and together they are the “Parties.” When signed by both Parties, this Agreement will set forth the terms and conditions under which RRD agrees to provide certain product development services to Eiger as set forth herein.
EIGER BIOPHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • November 9th, 2018 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of September 19, 2018, by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Company”), and RRD International, LLC, a Delaware limited liability company (the “Purchaser”).
